Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2020 16:05 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports Third Quarter 2020 Results and Provides Business Update

--Announces $18 million private placement-- --Submitted sNDAs for VAZALORE 325 mg and 81 mg doses to FDA end of October-- --On target for third quarter 2021 commercial launch of VAZALORE-- SPARTA,...
November 16, 2020 16:01 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Submits Supplemental New Drug Applications for VAZALORE™ 325 mg and 81 mg to U.S. Food and Drug Administration

-- FDA sets estimated completion review date for the end of February 2021 -- -- Targeting launch of VAZALORE for third quarter 2021 – SPARTA, N.J., Nov. 16, 2020 (GLOBE NEWSWIRE) -- PLx Pharma...
November 12, 2020 17:30 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020

SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated...
November 03, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Discuss 2020 Third Quarter Financial Results on November 13, 2020 Conference Call and Provide Business Update

SPARTA, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated...
September 14, 2020 16:30 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Present Virtually at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

SPARTA, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated...
August 14, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports Second Quarter 2020 Results and Provides Business Update

--Bioequivalence study of VAZALORE 325 mg on track with top-line data demonstrating bioequivalence to immediate release aspirin-- --Shifting the date of sNDA filings for VAZALORE 325 mg and 81 mg...
August 05, 2020 16:30 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Discuss 2020 Second Quarter Financial Results on August 14, 2020 Conference Call and Provide Business Update

SPARTA, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated...
May 18, 2020 16:30 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Announces Completion of $8 Million Convertible Preferred Stock Financing

SPARTA, N.J., May 18, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically...
May 15, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. Reports First Quarter 2020 Results

-- Company to begin bioequivalence study of VAZALORE 325 mg dose ---- sNDA submissions expected by year-end -- SPARTA, N.J., May 15, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx”...
May 04, 2020 06:50 ET | Source: PLx Pharma Inc.

PLx Pharma Inc. to Discuss 2020 First Quarter Financial Results on May 15, 2020 Conference Call

SPARTA, N.J., May 04, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically validated...